Medigene Ag

Boehringer Mannheim Gmbh

Medigene Oncology Gmbh

Syncore Biotechnology Co., Ltd.

Biomedical International R + D Gmbh

Ludwig-maximilians-universität

Uwe Michaelis

Gerhard Winter

Heinrich Haas

Michael Teifel

Thomas Fichert

Toralf Peymann

Christian Welz

Friedrich Gruber

Oliver Schramel

Brita Schulze

Carsten Mundus

Rainer Rudolph

Heinrich Woog

Erhard Kopetzki

Walter-Gunar Friebe

Michael Jarsch

Nikolaos Dimoudis

Helmut Burtscher

Erika Jensen-Jarolim

Margit Weghofer

Christoph Rehfuess

Christoph Brunner

Eric Guenzi

Martin Funk

Bernhard Knipp

Birgitta Sauer

Martin Eichhorn

Gether Schumacher

Birgitta Sauer-Stoschek

Kerstin Bartelheim

Hermann Bohnenkamp

Marcus Schmitt-Sody

Kurt Naujoks

The present invention relates to parvovirus mutated structural proteins comprising insertions of mimotopes of a HER2, compositions, multimeric structures, medicaments and vaccines comprising the same, nucleic acids, expression cassettes, constructs, vectors and cells comprising the nucleic acids, methods of preparing the structural proteins and methods of inducing a B-cell response or of treating a HER2-related disease.

Anti-HER2 vaccine based upon AAV derived multimeric structures

A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Method of producing a cationic liposomal preparation comprising a lipophilic compound

The present invention relates to new amino alcohol derivatives, process for the production thereof and medicaments and reagents containing these compounds.

Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds

Aqueous pharmaceutical preparations of G-CSF are disclosed that are stable on storage and a buffer selected from the group consisting of a salt of citrate, maleate, a combination of phosphate and citrate, and arginine; and at least one surfactant.

Aqueous pharmaceutical preparations of G-CSF with a long shelf life

Stable lyophilized pharmaceutical preparations of G-CSF

In a process for the production of recombinant, biologically active, eukaryotic alkaline phosphatase a DNA sequence coding for a eukaryotic alkaline phosphatase is expressed in a prokaryotic host cell and the expression product is obtained in an active form by cell lysis, solubilization under denaturing conditions and subsequent renaturation. In this process the renaturation step is carried out in the presence of one or several stabilizing agents.

Process for the production and renaturation of recombinant, biologically

Growing community of inventors

Weilheim, Germany

Uwe Michaelis